<DOC>
	<DOCNO>NCT01850966</DOCNO>
	<brief_summary>To investigate safety efficacy administration Iguratimod ( CRM01T ) 52 week patient rheumatoid arthritis clinical practice</brief_summary>
	<brief_title>Investigation Safety Efficacy Iguratimod Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion Participants rheumatoid arthritis Participants take iguratimod Exclusion criterion Participants register survey previously Pregnant woman woman suspect pregnant Participants serious liver disorder Participants peptic ulcer Participants know hypersensitivity iguratimod excipients</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Arthritis , Rheumatoid , Iguratimod</keyword>
</DOC>